SEC Opens Tysabri Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
The Securities & Exchange Commission has opened an investigation into the marketing suspension of Biogen Idec/Elan's multiple sclerosis therapy Tysabri (natalizumab)